Endocrine Therapy for Breast Cancer in the Primary Care Setting

Awan, Arif; Esfahani, Khashayar

doi:10.3747/co.25.4139

Cited by 44 publications

(62 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of invasive breast cancers are hormone receptorpositive (HR+) [1][2][3][4][5]. Endocrine therapy (ET), a key component of breast cancer treatment, reduces the risk of local and distant recurrence [2,[6][7][8].…”

Section: Introductionmentioning

confidence: 99%

How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support

et al. 2020

View full text Add to dashboard Cite

Purpose Many patients with hormone receptor-positive (HR+) breast cancer do not adhere to endocrine therapy (ET), and treatment-related side effects are often discussed by participants in online breast cancer forums. Our aim was to survey this unique group of patients about their ET-related experiences. Methods We partnered with patients active in breast cancer social media communities to develop a survey assessing ET-related side effects and medical team communication. Patients with a history of HR+ breast cancer who had received a recommendation to take ET were eligible to participate in the anonymous, online survey. Results Respondents included 2353 women and 54 men. Aromatase inhibitors were the most commonly used medication. Side effects were reported by 91.2%, were more often experienced by women than men (p < 0.001), and were primarily related to medication type. Approximately one-third of respondents discontinued therapy early. While most felt supported by their medical team, 31.5% reported that their side effects were dismissed or minimized. Survey respondents most frequently reported that a healthy diet and exercise, yoga/acupuncture, and vitamins/supplements were helpful in managing ET-related side effects. Conclusions ET-related side effects are very common, and one-third discontinued treatment early. Lifestyle changes and complementary therapies can be important tools for side effect management. One-third of patients did not feel that their side effects were taken seriously. Implications for Cancer Survivors This is the largest survey of ET use by participants in online breast cancer communities. Further research is needed to identify strategies to improve treatment adherence and to better manage ET-related side effects.

show abstract

Section: Introductionmentioning

confidence: 99%

How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Previous studies demonstrated that patient non-adherence to adjuvant endocrine therapy is primarily caused by the adverse side effects on patients' quality of life (QOL) that are associated with such therapy [8,9]. These common side effects may include hot flashes, night sweats, fatigue, sleep disturbance, sexual dysfunction, joint stiffness, joint dysfunction and joint pain [9][10][11][12][13]. These symptoms may also negatively affect patients' functional ability.…”

Section: Introductionmentioning

confidence: 99%

The Effects of Pharmacological and Non-Pharmacological Interventions on Symptom Management and Quality of Life among Breast Cancer Survivors Undergoing Adjuvant Endocrine Therapy: A Systematic Review

Chan

Tai

Kwong

et al. 2020

IJERPH

View full text Add to dashboard Cite

Breast cancer survivors need to undergo adjuvant endocrine therapy after completion of curative treatments to prevent disease recurrence. These individuals often experience symptoms which are detrimental to their quality of life (QOL). Implementation of interventions for effective symptom management among these survivors is warranted. This review provides an overview of studies on the effectiveness of the previously developed interventions for breast cancer survivors undergoing adjuvant endocrine therapy on symptom alleviation and enhancement of QOL or health-related QOL (HRQOL). Five electronic databases were employed in the literature search. Study selection, data extraction and critical appraisal of the included studies were conducted by three authors independently. Twenty-four studies were included. Both pharmacological and non-pharmacological interventions are effective in addressing the symptoms associated with adjuvant endocrine therapy among the breast cancer survivors, and in improving their QOL, although discrepancies were noted between the studies in terms of the significance of these effects. Pharmacological and non-pharmacological interventions can be effective for symptom management among breast cancer survivors. Their implementation is recommended for effective survivorship care for these individuals. Further research on intervention development for breast cancer survivors is recommended to provide further evidence for the utility of the explored interventions in survivorship care for these patients.

show abstract

“…Treatment options for BC include surgery, chemotherapy, radiation therapy, endocrine therapy, and combination therapy. 2,4,5 Understanding the effects of estrogen and androgen on BC is critically important for treating BC. PC is the main male sex hormone-dependent cancer.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer

Liu

Zhao

Zhang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Breast cancer (BC) and prostate cancer (PC) are the second most common malignant tumors in women and men in western countries, respectively. The risks of death are 14% for BC and 9% for PC. Abnormal estrogen and androgen levels are related to carcinogenesis of the breast and prostate. Estradiol stimulates cancer development in BC. The effect of estrogen on PC is concentration‐dependent, and estrogen can regulate androgen production, further affecting PC. Estrogen can also increase the risk of androgen‐induced PC. Androgen has dual effects on BC via different metabolic pathways, and the role of the androgen receptor (AR) in BC also depends on cell subtype and downstream target genes. Androgen and AR can stimulate both primary PC and castration‐resistant PC. Understanding the mechanisms of the effects of estrogen and androgen on BC and PC may help us to improve curative BC and PC treatment strategies.

show abstract

Endocrine Therapy for Breast Cancer in the Primary Care Setting

Cited by 44 publications

References 46 publications

How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support

How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support

The Effects of Pharmacological and Non-Pharmacological Interventions on Symptom Management and Quality of Life among Breast Cancer Survivors Undergoing Adjuvant Endocrine Therapy: A Systematic Review

Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer

Contact Info

Product

Resources

About